Summary
Clinicians at Norway's national gender service used its own records to trace every child and teenager referred over 20 years. Of 1,258 referred, 62% went on to cross-sex hormones. Nearly all of the 11% given puberty blockers (97%) moved on to hormones. 22% of those who attended left without any medical treatment. Eighteen females stopped testosterone and detransitioned, and 11 people in the group died, though causes of death were not recorded. The authors admit the detransition count is probably too low, because people who stop often drop out of the clinic's sight. In July 2026 the journal withdrew (retracted) the paper after a research-integrity panel found it lacked ethics committee approval and patient consent. Five authors were found to have committed misconduct, which they are appealing. Its figures should not be quoted as settled evidence.
Key findings
- पत्रिका ने जुलाई 2026 में शोधपत्र वापस ले लिया क्योंकि शोध के पास नॉर्वे की चिकित्सा शोध नैतिकता समिति की मंज़ूरी और मरीज़ों की उचित सहमति नहीं थी। वापसी का मतलब यह नहीं था कि डेटा में त्रुटियाँ थीं।
- 2000 से 2020 तक भेजे गए 1,258 बच्चों और किशोरों में से 861 (68.4%) महिला जन्मे थे, और रेफ़र किए जाने के समय औसत आयु 14.4 वर्ष थी।
- 135 (10.7%) ने प्यूबर्टी ब्लॉकर्स शुरू किए, पुरुष जन्मे लोगों में अधिक बार, और उनमें से 97% क्रॉस-सेक्स हार्मोन पर चले गए।
- रेफ़र किए गए सभी लोगों में से 783 (62.2%) ने क्रॉस-सेक्स हार्मोन शुरू किए।
- कम से कम एक मुलाकात में आए 1,198 में से 264 (22.0%) बिना किसी लिंग-संबंधी चिकित्सीय इलाज के क्लिनिक छोड़ गए।
- हार्मोन बंद करने वाले दर्ज सभी 18 लोग (शुरू करने वाले 783 में से 2.3%) महिला जन्मे थे और उन्होंने 2015 से 2021 के बीच टेस्टोस्टेरोन शुरू किया था। 11 अब खुद को ट्रांस नहीं मानते थे; 7 अब भी मानते थे (5 अपने हुए बदलावों से खुश थे, 2 को प्रजनन क्षमता की चिंता थी)।
- 1,258 में से ग्यारह (0.9%) की 2023 के अंत तक मृत्यु हो चुकी थी; मृत्यु के कारण उपलब्ध नहीं थे।
Abstract
Aim: We aimed to describe treatment trajectories, detransition and mortality rate among children and adolescents referred to the Norwegian National Center for Gender Incongruence (NCGI). Methods: The cohort included all 1258 persons under 18 years at referral to the NCGI from 2000 to 2020. Trajectories were registered until end of 2023. Results: In total, 861/1258 (68.4%) were assigned female gender at birth (AFAB). Mean age at referral was 14.4 years. Puberty suppression with gonadotropin-releasing hormone agonists (GnRHa) was initiated among 135/1258 (10.7%), significantly more persons assigned male gender at birth (AMAB) than AFAB (p < 0.001). Gender-affirming hormonal treatment (GAHT) was initiated in 783/1258 (62.2%). The continuation rate from GnRHa to GAHT was 97%. Discharge rate from NCGI without gender-affirming medical treatment among those who attended at least one appointment, was 264/1198 (22.0%). Eighteen AFAB detransitioned after initiated GAHT, eleven due to a cessation of transgender identity. Mortality rate in the cohort until end of 2023 was 11/1258 (0.9%). Conclusion: Different trajectories including medical pathways and assessments without gender-affirming treatment were observed. GAHT was initiated in 783/1258 (62.2%), including eighteen AFAB detransitioning after testosterone treatment. There was a high continuation rate from GnRHa to GAHT. Various trajectories highlights the need for long-term follow-up in care.
Conclusion
This study provides valuable insights to gender-affirming care for children and adolescents, owing to its large sample size, including all children and adolescents referred to a national gender clinic over two decades. The study reports varying trajectories, encompassing both medical pathways and assessments ended without gender-affirming medical treatment. Our findings highlight the necessity for long-term follow-up and support of people referred to gender clinics. There is a need for ongoing research on gender-affirming treatment in young people to evaluate the short- and long-term benefits and risks of early treatment interventions, as well as patient-reported outcome measures.